标题
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
作者
关键词
Hypoxia-activated prodrugs, TH-302, AQ4N, EO9, Tirapazamine, PR-104, TH-4000, Hypoxia, Bioreductive drugs
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 77, Issue 3, Pages 441-457
出版商
Springer Nature
发表日期
2016-01-25
DOI
10.1007/s00280-015-2920-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia
- (2015) D. Moradi Manesh et al. BLOOD
- Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
- (2015) Fanying Meng et al. BMC CANCER
- Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
- (2015) C Yoon et al. BRITISH JOURNAL OF CANCER
- Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
- (2015) Jessica D Sun et al. CANCER BIOLOGY & THERAPY
- Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma
- (2015) Maria R Abbattista et al. CANCER BIOLOGY & THERAPY
- Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma
- (2015) Vasilios Liapis et al. CANCER LETTERS
- Hypoxia Induces Production of L-2-Hydroxyglutarate
- (2015) Andrew M. Intlekofer et al. Cell Metabolism
- Hypoxia-Mediated Increases in l -2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress
- (2015) William M. Oldham et al. Cell Metabolism
- Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases
- (2015) Roben G. Gieling et al. CLINICAL & EXPERIMENTAL METASTASIS
- TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
- (2015) S. G. J. A. Peeters et al. CLINICAL CANCER RESEARCH
- Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation--An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302
- (2015) J. K. Saggar et al. CLINICAL CANCER RESEARCH
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
- (2015) M. Konopleva et al. HAEMATOLOGICA
- Interplay between receptor tyrosine kinases and hypoxia signaling in cancer
- (2015) Astrid A. Glück et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- HIF-1 at the crossroads of hypoxia, inflammation, and cancer
- (2015) Kuppusamy Balamurugan INTERNATIONAL JOURNAL OF CANCER
- Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
- (2015) Mitesh J. Borad et al. JOURNAL OF CLINICAL ONCOLOGY
- Global Profiling of Metabolic Adaptation to Hypoxic Stress in Human Glioblastoma Cells
- (2015) Paulina Kucharzewska et al. PLoS One
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
- (2015) M. Konopleva et al. HAEMATOLOGICA
- Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation
- (2014) Claudia Karnthaler-Benbakka et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Hypoxia-Targeted siRNA Delivery
- (2014) F. Perche et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs
- (2014) Francis W. Hunter et al. BIOCHEMICAL PHARMACOLOGY
- Autophagy: An adaptive metabolic response to stress shaping the antitumor immunity
- (2014) Elodie Viry et al. BIOCHEMICAL PHARMACOLOGY
- HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion
- (2014) Isabel M Pires et al. CANCER BIOLOGY & THERAPY
- Hypoxic Regulation of Glutamine Metabolism through HIF1 and SIAH2 Supports Lipid Synthesis that Is Necessary for Tumor Growth
- (2014) Ramon C. Sun et al. Cell Metabolism
- The Meaning, Measurement and Modification of Hypoxia in the Laboratory and the Clinic
- (2014) E.M. Hammond et al. CLINICAL ONCOLOGY
- Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis: A Gynecologic Oncology Group Study
- (2014) Paul A. DiSilvestro et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
- (2014) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer
- (2014) Mateya E Trinkaus et al. Journal of Medical Imaging and Radiation Oncology
- Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer
- (2014) F. W. Hunter et al. MOLECULAR CANCER THERAPEUTICS
- Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000
- (2014) Robert F. Anderson et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment
- (2014) Jun Ye et al. TUMOR BIOLOGY
- CH-01 is a Hypoxia-Activated Prodrug That Sensitizes Cells to Hypoxia/Reoxygenation Through Inhibition of Chk1 and Aurora A
- (2013) Cindy Cazares-Körner et al. ACS Chemical Biology
- Imaging Tumor Hypoxia to Advance Radiation Oncology
- (2013) Chen-Ting Lee et al. ANTIOXIDANTS & REDOX SIGNALING
- Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors
- (2013) M Ahmadi et al. BRITISH JOURNAL OF PHARMACOLOGY
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
- (2013) S. Portwood et al. CLINICAL CANCER RESEARCH
- Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy
- (2013) Jasdeep K. Saggar et al. INTERNATIONAL JOURNAL OF CANCER
- Hypoxia-Selective O6-Alkylguanine-DNA Alkyltransferase Inhibitors: Design, Synthesis, and Evaluation of 6-(Benzyloxy)-2-(aryldiazenyl)-9H-purines as Prodrugs of O6-Benzylguanine
- (2013) Rui Zhu et al. JOURNAL OF MEDICINAL CHEMISTRY
- 18F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non-Small Cell Lung Cancer Xenograft Model
- (2013) S. K. Chitneni et al. JOURNAL OF NUCLEAR MEDICINE
- Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro
- (2013) J. Hu et al. MOLECULAR CANCER THERAPEUTICS
- Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
- (2013) Christopher P. Guise et al. Chinese Journal of Cancer
- PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
- (2012) Mark J McKeage et al. BMC CANCER
- EO9 (Apaziquone): from the clinic to the laboratory and back again
- (2012) Roger M Phillips et al. BRITISH JOURNAL OF PHARMACOLOGY
- Imaging Tumor Sensitivity to a Bioreductive Prodrug: Two for the Price of One!
- (2012) J. M. Brown CLINICAL CANCER RESEARCH
- Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer
- (2012) Q.-T. Le et al. CLINICAL CANCER RESEARCH
- Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: Informed scheduling of the bioreductive drug AQ4N improves treatment response
- (2012) Louise Ming et al. INTERNATIONAL JOURNAL OF CANCER
- A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
- (2011) Mark J McKeage et al. BMC CANCER
- PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
- (2011) Ghassan K. Abou-Alfa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer
- (2011) Q. Chang et al. CANCER RESEARCH
- Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial
- (2011) A. M. Lim et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
- (2011) G. J. Weiss et al. CLINICAL CANCER RESEARCH
- Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy
- (2011) Y. Gu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
- (2011) F. Meng et al. MOLECULAR CANCER THERAPEUTICS
- A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
- (2011) Kristen N. Ganjoo et al. ONCOLOGY
- Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
- (2011) Juliana Benito et al. PLoS One
- The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3
- (2010) C. P. Guise et al. CANCER RESEARCH
- Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group
- (2010) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
- (2010) Lester J. Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program
- (2010) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
- Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies
- (2010) Renaud Grépin et al. Journal of Oncology
- A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
- (2009) Michael B. Jameson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone
- (2009) O. Tredan et al. CANCER RESEARCH
- Pharmacologically Increased Tumor Hypoxia Can Be Measured by 18F-Fluoroazomycin Arabinoside Positron Emission Tomography and Enhances Tumor Response to Hypoxic Cytotoxin PR-104
- (2009) R. A. Cairns et al. CLINICAL CANCER RESEARCH
- Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222
- (2009) Quynh-Thu X. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Spin Trapping of Radicals Other Than the•OH Radical upon Reduction of the Anticancer Agent Tirapazamine by Cytochrome P450Reductase
- (2009) Sujata S. Shinde et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N)
- (2009) M. Mehibel et al. MOLECULAR CANCER THERAPEUTICS
- Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A
- (2009) Y. Gu et al. MOLECULAR CANCER THERAPEUTICS
- In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts
- (2009) K. J. Williams et al. MOLECULAR CANCER THERAPEUTICS
- Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates
- (2009) Arun Jain et al. UROLOGY
- Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
- (2009) Kees Hendricksen et al. WORLD JOURNAL OF UROLOGY
- Evaluation of the Antiangiogenic Potential of AQ4N
- (2008) M. O'Rourke et al. CLINICAL CANCER RESEARCH
- Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study
- (2008) M. R. Albertella et al. CLINICAL CANCER RESEARCH
- A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
- (2008) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non–Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003
- (2008) Philip C. Mack et al. JOURNAL OF CLINICAL ONCOLOGY
- Reductive Heme-Dependent Activation of theN-Oxide Prodrug AQ4N by Nitric Oxide Synthase
- (2008) Clinton R. Nishida et al. JOURNAL OF MEDICINAL CHEMISTRY
- Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
- (2008) Jian-Xin Duan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Side Effects of Immediate Instillation of Apaziquone Following Transurethral Resection in Patients With Nonmuscle Invasive Bladder Cancer
- (2008) K. Hendricksen et al. JOURNAL OF UROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search